Suppr超能文献

非酒精性脂肪性肝病与结直肠癌生存率

Non-alcoholic fatty liver disease and colorectal cancer survival.

作者信息

Wu Kana, Zhai Mike Z, Weltzien Erin K, Cespedes Feliciano Elizabeth M, Meyerhardt Jeffrey A, Giovannucci Edward, Caan Bette J

机构信息

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

出版信息

Cancer Causes Control. 2019 Feb;30(2):165-168. doi: 10.1007/s10552-018-1095-z. Epub 2018 Nov 15.

Abstract

PURPOSE

Liver diseases including non-alcoholic fatty liver disease (NAFLD) and ensuing alterations to the micro-environment may affect development of liver metastasis. Mirroring the rise in obesity rates, prevalence of NAFLD is increasing globally. Our objective was to examine the association between NAFLD and mortality in colorectal cancer patients.

METHODS

Colorectal Cancer-Sarcopenia and Near-term Survival (C-SCANS) is a retrospective cohort study which included 3,262 stage I-III patients, aged 18-80 years, and diagnosed between 2006 and 2011 at Kaiser Permanente Northern California. Cox proportional hazards regression was used to calculate multivariable adjusted hazard ratios (HR) and 95% confidence intervals (CI).

RESULTS

After up to 10 years of follow-up, 879 deaths, including 451 from CRC were identified. Cases diagnosed with NAFLD before and within 1 month after CRC diagnosis (pre-existing NAFLD; n = 83) had a HR of 1.64 (95% CI 1.06-2.54) for overall and a HR of 1.85 (95% CI 1.03-3.30) for CRC-specific mortality compared to those without NAFLD. Findings did not differ significantly by sex, stage, tumor location, and smoking status, and were also similar when restricted to obese patients only.

CONCLUSIONS

Independent of body mass index and prognostic indicators, CRC patients with pre-existing NAFLD had a worse prognosis than those without NAFLD.

摘要

目的

包括非酒精性脂肪性肝病(NAFLD)在内的肝脏疾病以及随之而来的微环境改变可能会影响肝转移的发生。随着肥胖率的上升,NAFLD在全球的患病率也在增加。我们的目的是研究NAFLD与结直肠癌患者死亡率之间的关联。

方法

结直肠癌-肌肉减少症与近期生存率(C-SCANS)是一项回顾性队列研究,纳入了3262例年龄在18至80岁之间、于2006年至2011年在北加利福尼亚州凯撒医疗集团确诊为I-III期的患者。采用Cox比例风险回归分析来计算多变量调整后的风险比(HR)和95%置信区间(CI)。

结果

经过长达10年的随访,共确定了879例死亡病例,其中包括451例死于结直肠癌。与无NAFLD的患者相比,在结直肠癌诊断前及诊断后1个月内被诊断为NAFLD的患者(即既往存在NAFLD;n = 83)的全因死亡HR为1.64(95% CI 1.06 - 2.54),结直肠癌特异性死亡HR为1.85(95% CI 1.03 - 3.30)。研究结果在性别、分期、肿瘤位置和吸烟状况方面无显著差异,仅纳入肥胖患者时结果也相似。

结论

独立于体重指数和预后指标,既往存在NAFLD的结直肠癌患者的预后比无NAFLD的患者更差。

相似文献

1
Non-alcoholic fatty liver disease and colorectal cancer survival.
Cancer Causes Control. 2019 Feb;30(2):165-168. doi: 10.1007/s10552-018-1095-z. Epub 2018 Nov 15.
2
Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis.
Medicine (Baltimore). 2015 Feb;94(5):e479. doi: 10.1097/MD.0000000000000479.
3
Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams.
JAMA Oncol. 2016 Sep 1;2(9):1137-45. doi: 10.1001/jamaoncol.2016.0732.
5
The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer.
Expert Rev Gastroenterol Hepatol. 2019 Dec;13(12):1169-1180. doi: 10.1080/17474124.2019.1697231. Epub 2019 Nov 29.
6
Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
World J Gastroenterol. 2016 Mar 14;22(10):3023-30. doi: 10.3748/wjg.v22.i10.3023.
7
Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study.
J Gastrointest Cancer. 2024 Jun;55(2):932-939. doi: 10.1007/s12029-024-01042-6. Epub 2024 Mar 19.
8
Association between nonalcoholic fatty liver disease and colorectal cancer: A population-based study.
Medicine (Baltimore). 2023 May 26;102(21):e33867. doi: 10.1097/MD.0000000000033867.
9
Non-alcoholic fatty liver diseases and risk of colorectal neoplasia.
Aliment Pharmacol Ther. 2017 Jan;45(2):345-353. doi: 10.1111/apt.13866. Epub 2016 Nov 18.
10
Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
World J Gastroenterol. 2015 Aug 28;21(32):9607-13. doi: 10.3748/wjg.v21.i32.9607.

引用本文的文献

3
Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes: The DIRECT PLUS clinical trial.
Hepatology. 2025 Jan 1;81(1):198-211. doi: 10.1097/HEP.0000000000000867. Epub 2024 Mar 27.
4
Unveiling the cancer risk nexus of the steatotic liver.
Trends Endocrinol Metab. 2024 Aug;35(8):708-719. doi: 10.1016/j.tem.2024.02.017. Epub 2024 Mar 25.
5
Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD.
Mol Cells. 2024 Feb;47(2):100010. doi: 10.1016/j.mocell.2024.100010. Epub 2024 Jan 17.
6
New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk.
JAMA Netw Open. 2023 Sep 5;6(9):e2335511. doi: 10.1001/jamanetworkopen.2023.35511.
7
Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment.
Cell Metab. 2023 Jul 11;35(7):1209-1226.e13. doi: 10.1016/j.cmet.2023.04.013. Epub 2023 May 11.
9
The molecular basis of the associations between non-alcoholic fatty liver disease and colorectal cancer.
Front Genet. 2022 Dec 9;13:1007337. doi: 10.3389/fgene.2022.1007337. eCollection 2022.

本文引用的文献

1
Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
PLoS One. 2017 Mar 27;12(3):e0173499. doi: 10.1371/journal.pone.0173499. eCollection 2017.
2
Colorectal cancer statistics, 2017.
CA Cancer J Clin. 2017 May 6;67(3):177-193. doi: 10.3322/caac.21395. Epub 2017 Mar 1.
3
Association of Weight Change after Colorectal Cancer Diagnosis and Outcomes in the Kaiser Permanente Northern California Population.
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):30-37. doi: 10.1158/1055-9965.EPI-16-0145. Epub 2016 Dec 16.
4
Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer.
J Clin Oncol. 2016 Oct 20;34(30):3664-3671. doi: 10.1200/JCO.2016.67.4473.
5
The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health.
Hepatology. 2016 Jul;64(1):19-22. doi: 10.1002/hep.28524. Epub 2016 Apr 4.
6
Global patterns and trends in colorectal cancer incidence and mortality.
Gut. 2017 Apr;66(4):683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27.
8
Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis.
Medicine (Baltimore). 2015 Feb;94(5):e479. doi: 10.1097/MD.0000000000000479.
9
Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis.
PLoS One. 2014 Sep 29;9(9):e108618. doi: 10.1371/journal.pone.0108618. eCollection 2014.
10
Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer.
Int J Colorectal Dis. 2013 Aug;28(8):1065-72. doi: 10.1007/s00384-013-1656-2. Epub 2013 Feb 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验